{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T12:11:20Z","timestamp":1778155880795,"version":"3.51.4"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Chongqing University of Medical Science: Chongqing Medical University","award":["ZHYX202222"],"award-info":[{"award-number":["ZHYX202222"]}]},{"name":"Chongqing University of Medical Science: Chongqing Medical University","award":["ZHYX202222"],"award-info":[{"award-number":["ZHYX202222"]}]},{"name":"Chongqing University of Medical Science: Chongqing Medical University","award":["ZHYX202222"],"award-info":[{"award-number":["ZHYX202222"]}]},{"name":"Chongqing University of Medical Science: Chongqing Medical University","award":["ZHYX202222"],"award-info":[{"award-number":["ZHYX202222"]}]},{"name":"Chongqing University of Medical Science: Chongqing Medical University","award":["ZHYX202222"],"award-info":[{"award-number":["ZHYX202222"]}]},{"name":"Chongqing Science and Technology Bureau Natural Science Fund project","award":["CSTB2024NSCQ-KJFZMSX0015"],"award-info":[{"award-number":["CSTB2024NSCQ-KJFZMSX0015"]}]},{"name":"Chongqing Science and Technology Bureau Natural Science Fund project","award":["CSTB2024NSCQ-KJFZMSX0015"],"award-info":[{"award-number":["CSTB2024NSCQ-KJFZMSX0015"]}]},{"name":"Chongqing Science and Technology Bureau Natural Science Fund project","award":["CSTB2024NSCQ-KJFZMSX0015"],"award-info":[{"award-number":["CSTB2024NSCQ-KJFZMSX0015"]}]},{"name":"Chongqing Science and Technology Bureau Natural Science Fund project","award":["CSTB2024NSCQ-KJFZMSX0015"],"award-info":[{"award-number":["CSTB2024NSCQ-KJFZMSX0015"]}]},{"name":"Chongqing Science and Technology Bureau Natural Science Fund project","award":["CSTB2024NSCQ-KJFZMSX0015"],"award-info":[{"award-number":["CSTB2024NSCQ-KJFZMSX0015"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-15621-2","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T10:12:34Z","timestamp":1774692754000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Chemoresistance and genetic mutations in hepatocellular carcinoma: a pharmacogenomic atlas of 51 patients"],"prefix":"10.1186","volume":"26","author":[{"given":"Hong-Han","family":"Jiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guo-Ying","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Dong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Zhou","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng-Rong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,28]]},"reference":[{"key":"15621_CR1","doi-asserted-by":"publisher","unstructured":"Siegel Rebecca SHFJ, Mathieu LL, Soerjomataram Isabelle, Jemal Ahmedin, Bray Freddie. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660.","DOI":"10.3322\/caac.21660"},{"key":"15621_CR2","doi-asserted-by":"crossref","unstructured":"Rebecca L. Siegel1,Kimberly D Miller1,Hannah E Fuchs1,Ahmedin Jemal, cancer statistics, 2022. CA. Cancer J Clin. 2022;72:7\u201333.","DOI":"10.3322\/caac.21708"},{"key":"15621_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL. Miller KD,Jemal A.Cancer statistics,2018.CA. Cancer J Clin. 2018;68:7\u201330.","journal-title":"Cancer J Clin"},{"key":"15621_CR4","doi-asserted-by":"publisher","first-page":"69","DOI":"10.14218\/jcth.2017.00031","volume":"6","author":"S Daher","year":"2018","unstructured":"Daher S, Massarwa M, Benson AA. T.Current and future treatment of hepatocellular carcinoma:an updated comprehensive review. J Clin Transl Hepatol. 2018;6:69\u201378. https:\/\/doi.org\/10.14218\/jcth.2017.00031.","journal-title":"J Clin Transl Hepatol"},{"key":"15621_CR5","doi-asserted-by":"publisher","unstructured":"Lohitesh K, Chowdhury R. Mukherjee S.Resistance a major hindranceto chemotherapy in hepatocellular carcinoma:an insight[J].CancerCell int, 2018, 18:44. https:\/\/doi.org\/10.1186\/s12935-018-0538-7","DOI":"10.1186\/s12935-018-0538-7"},{"key":"15621_CR6","unstructured":"Chen ZQXH, Hu MM, et al. Recent progress in treatment of hepa-tocellular carcinoma. Am J Cancer Res. 2020;10(9):29933036."},{"issue":"4","key":"15621_CR7","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3760\/cma.j.cn501113-20220413-00193","volume":"30","author":"National Health Commission of the People\u2019s Republic of China, Medical Administration Bureau","year":"2022","unstructured":"National Health Commission of the People\u2019s Republic of China, Medical Administration Bureau. Guidelines for diagnosis and treatment of primary liver cancer (2022 edition). Chin J Hepatol. 2022;30(4):367\u201388. https:\/\/doi.org\/10.3760\/cma.j.cn501113-20220413-00193.","journal-title":"Chin J Hepatol"},{"key":"15621_CR8","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1038\/s41467-020-15403-9","volume":"11","author":"S Zhu","year":"2020","unstructured":"Zhu S, Wang JZ, Chen D, He YT, Meng N, Chen M, et al. An oncopeptide regulates mA recognition by the mA reader IGF2BP1 and tumorigenesis. Nat Commun. 2020;11:1685.","journal-title":"Nat Commun"},{"key":"15621_CR9","unstructured":"Duan B, Huang C, Bai J, Zhang YL,Wang X,Yang J. Multidrug Resistance in Hepatocellular Carcinoma. In: Tirnitz-Parker JEE,editor. Hepatocellular Carcinoma [Internet]. Brisbane(AU): Codon Publications; 2019 Oct 24. Chapter 8."},{"key":"15621_CR10","doi-asserted-by":"publisher","unstructured":"Li P, Lin Y, Zhang Y, Zhu Z, Huo K. SSX2IP promotes metastasis and chemotherapeutic resistance of hepatocellular carcinoma. J transl Med. 2013;11:52. https:\/\/doi.org\/10.1186\/1479-5876-11-52","DOI":"10.1186\/1479-5876-11-52"},{"key":"15621_CR11","doi-asserted-by":"publisher","first-page":"5969716","DOI":"10.1155\/2022\/5969716","volume":"2022","author":"GY Feng","year":"2022","unstructured":"Feng GY, Cheng Y, Chen K, Shi ZR. Correlation between immunohistochemical markers in hepatocellular carcinoma cells and in vitro High-Throughput drug sensitivity screening. Can J Gastroenterol Hepatol. 2022;2022:5969716. https:\/\/doi.org\/10.1155\/2022\/5969716.","journal-title":"Can J Gastroenterol Hepatol"},{"issue":"10","key":"15621_CR12","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1038\/s41588-018-0204-y","volume":"50","author":"AO Giacomelli","year":"2018","unstructured":"Giacomelli AO, Yang X, Lintner RE, McFarland JM, Duby M, Kim J, et al. Mutational processes shape the landscape of TP53 mutations in human cancer. Nat Genet. 2018;50(10):1381\u20137. https:\/\/doi.org\/10.1038\/s41588-018-0204-y.","journal-title":"Nat Genet"},{"issue":"12","key":"15621_CR13","doi-asserted-by":"publisher","first-page":"101186","DOI":"10.1016\/j.jhepr.2024.101186","volume":"6","author":"BM Lehrich","year":"2024","unstructured":"Lehrich BM, Tao J, Liu S, Hirsch TZ, Yasaka TM, Cao C, et al. Development of mutated \u03b2-catenin gene signature to identify CTNNB1 mutations from whole and Spatial transcriptomic data in patients with HCC. JHEP Rep. 2024;6(12):101186. https:\/\/doi.org\/10.1016\/j.jhepr.2024.101186.","journal-title":"JHEP Rep"},{"issue":"5","key":"15621_CR14","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1172\/JCI134402","volume":"130","author":"J Li","year":"2020","unstructured":"Li J, Wang W, Zhang Y, Cie\u015blik M, Guo J, Tan M, et al. Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy. J Clin Invest. 2020;130(5):2712\u201326. https:\/\/doi.org\/10.1172\/JCI134402.","journal-title":"J Clin Invest"},{"issue":"9","key":"15621_CR15","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1158\/0008-5472.CAN-23-2268","volume":"84","author":"R Zhang","year":"2024","unstructured":"Zhang R, Li S, Schippers K, Li Y, Eimers B, Lavrijsen M, et al. Analysis of Tumor-Associated AXIN1 missense mutations identifies variants that activate \u03b2-Catenin signaling. Cancer Res. 2024;84(9):1443\u201359. https:\/\/doi.org\/10.1158\/0008-5472.CAN-23-2268.","journal-title":"Cancer Res"},{"issue":"12","key":"15621_CR16","doi-asserted-by":"publisher","first-page":"e0338","DOI":"10.1097\/HC9.0000000000000338","volume":"7","author":"FY Huang","year":"2023","unstructured":"Huang FY, Wong DK, Mak LY, Cheung TT, Zhang SS, Chau HT, et al. FAT4 loss initiates hepatocarcinogenesis through the switching of canonical to noncanonical WNT signaling pathways. Hepatol Commun. 2023;7(12):e0338. https:\/\/doi.org\/10.1097\/HC9.0000000000000338.","journal-title":"Hepatol Commun"},{"issue":"5","key":"15621_CR17","first-page":"2784","volume":"11","author":"X Che","year":"2019","unstructured":"Che X, Jian F, Jia N, Zheng Y, Jiang Y, Feng W. FAT4-USP51 complex regulates the proliferation and invasion of endometrial cancer via Hippo pathway. Am J Transl Res. 2019;11(5):2784\u2013800.","journal-title":"Am J Transl Res"},{"issue":"21","key":"15621_CR18","doi-asserted-by":"publisher","first-page":"907","DOI":"10.4254\/wjh.v9.i21.907","volume":"9","author":"M Le Grazie","year":"2017","unstructured":"Le Grazie M, Biagini MR, Tarocchi M, Polvani S, Galli A. Chemotherapy for hepatocellular carcinoma: the present and the future. World J Hepatol. 2017;9(21):907\u201320. https:\/\/doi.org\/10.4254\/wjh.v9.i21.907.","journal-title":"World J Hepatol"},{"key":"15621_CR19","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/s41556-018-0045-z","volume":"20","author":"H Huang","year":"2018","unstructured":"Huang H, Weng H, Sun W, Qin X, Shi H, Wu H, et al. Recognition of RNA N-methyladenosine by IGF2BP proteins enhances mRNA stability and translation. Nat Cell Biol. 2018;20:285\u201395.","journal-title":"Nat Cell Biol"},{"issue":"1","key":"15621_CR20","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12964-018-0260-z","volume":"16","author":"L Wu","year":"2018","unstructured":"Wu L, Pan C, Wei X, Shi Y, Zheng J, Lin X, et al. LncRNA KRAL reverses 5-fluorouracil resistance in hepatocellular carcinoma cells by acting as a CeRNA against miR-141. Cell Commun Signal. 2018;16(1):47. https:\/\/doi.org\/10.1186\/s12964-018-0260-z.","journal-title":"Cell Commun Signal"},{"issue":"2","key":"15621_CR21","doi-asserted-by":"publisher","first-page":"101201","DOI":"10.1016\/j.esmoop.2023.101201","volume":"8","author":"M Li","year":"2023","unstructured":"Li M, Mindt S, L\u00fcck A, Hutzschenreuter U, Kollendt M, Lathan B, et al. Drug monitoring detects under- and overdosing in patients receiving 5-fluorouracil-containing chemotherapy-results of a prospective, multicenter German observational study. ESMO Open. 2023;8(2):101201. https:\/\/doi.org\/10.1016\/j.esmoop.2023.101201.","journal-title":"ESMO Open"},{"issue":"11","key":"15621_CR22","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1021\/acsptsci.2c00117","volume":"5","author":"H Verma","year":"2022","unstructured":"Verma H, Narendra G, Raju B, Singh PK, Silakari O. Dihydropyrimidine Dehydrogenase-Mediated resistance to 5-Fluorouracil: mechanistic investigation and solution. ACS Pharmacol Transl Sci. 2022;5(11):1017\u201333. https:\/\/doi.org\/10.1021\/acsptsci.2c00117.","journal-title":"ACS Pharmacol Transl Sci"},{"key":"15621_CR23","doi-asserted-by":"publisher","first-page":"103207","DOI":"10.1016\/j.redox.2024.103207","volume":"73","author":"S Dong","year":"2024","unstructured":"Dong S, Zhang M, Cheng Z, Zhang X, Liang W, Li S, et al. Redistribution of defective mitochondria-mediated dihydroorotate dehydrogenase imparts 5-fluorouracil resistance in colorectal cancer. Redox Biol. 2024;73:103207.","journal-title":"Redox Biol"},{"issue":"1","key":"15621_CR24","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s13046-019-1043-0","volume":"38","author":"R Wei","year":"2019","unstructured":"Wei R, Xiao Y, Song Y, Yuan H, Luo J, Xu W. FAT4 regulates the EMT and autophagy in colorectal cancer cells in part via the PI3K-AKT signaling axis. J Exp Clin Cancer Res. 2019;38(1):112. https:\/\/doi.org\/10.1186\/s13046-019-1043-0.","journal-title":"J Exp Clin Cancer Res"},{"issue":"12","key":"15621_CR25","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/bjc.2015.367","volume":"113","author":"J Cai","year":"2015","unstructured":"Cai J, Feng D, Hu L, Chen H, Yang G, Cai Q, et al. FAT4 functions as a tumour suppressor in gastric cancer by modulating Wnt\/\u03b2-catenin signalling. Br J Cancer. 2015;113(12):1720\u20139. https:\/\/doi.org\/10.1038\/bjc.2015.367.","journal-title":"Br J Cancer"},{"key":"15621_CR26","doi-asserted-by":"publisher","unstructured":"Yang Y, Li Y, Yang Q, Liu Z, Chang X, Yang H, et al. FAT4 activation inhibits epithelial-mesenchymal transition (EMT) by promoting autophagy in H2228\/Cer cells. Med Oncol. 2022;40(1):64. https:\/\/doi.org\/10.1007\/s12032-022-01934-2.","DOI":"10.1007\/s12032-022-01934-2"},{"key":"15621_CR27","doi-asserted-by":"crossref","unstructured":"Fischer KR, Durrans A, Lee S, Sheng J, Li F, Wong ST, et al. Epithelial-to\u2010mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature. 2015;527(7579):472\u2010610.1038\/nature15748.","DOI":"10.1038\/nature15748"},{"issue":"12","key":"15621_CR28","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1001\/jamaoncol.2023.4003","volume":"9","author":"S Qin","year":"2023","unstructured":"Qin S, Kudo M, Meyer T, Bai Y, Guo Y, Meng Z, et al. Tislelizumab vs Sorafenib as First-Line treatment for unresectable hepatocellular carcinoma: A phase 3 randomized clinical trial. JAMA Oncol. 2023;9(12):1651\u20139.\u00a0https:\/\/doi.org\/10.1001\/jamaoncol.2023.4003.","journal-title":"JAMA Oncol"},{"issue":"2","key":"15621_CR29","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.jcmgh.2020.02.009","volume":"10","author":"T Hashiba","year":"2020","unstructured":"Hashiba T, Yamashita T, Okada H, Nio K, Hayashi T, Asahina Y, et al. Inactivation of transcriptional repressor capicua confers Sorafenib resistance in human hepatocellular carcinoma. Cell Mol Gastroenterol Hepatol. 2020;10(2):269\u201385.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"15621_CR30","doi-asserted-by":"publisher","unstructured":"Moreno CS, Winham CL, Alemozaffar M, Klein ER, Lawal IO, et al. Cancers (Basel). 2023;15(23):5671. https:\/\/doi.org\/10.3390\/cancers15235671.","DOI":"10.3390\/cancers15235671"},{"issue":"3","key":"15621_CR31","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1159\/000534889","volume":"91","author":"M Bernhardt","year":"2024","unstructured":"Bernhardt M, Behrens HM, Kr\u00fcger S, R\u00f6cken C. Exploration of the tumour biological significance of PCLO in gastric cancer: results from a large central European cohort. Pathobiology. 2024;91(3):187\u201395. https:\/\/doi.org\/10.1159\/000534889.","journal-title":"Pathobiology"},{"key":"15621_CR32","doi-asserted-by":"publisher","unstructured":"Kudo M. Lenvatinib May Drastically Change the Treatment Landscape of Hepatocellular Carcinoma. Liver Cancer. 2018;7(1):1\u201319. https:\/\/doi.org\/10.1159\/000487148.","DOI":"10.1159\/000487148"},{"issue":"1","key":"15621_CR33","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s00535-019-01642-1","volume":"55","author":"T Yamashita","year":"2020","unstructured":"Yamashita T, Kudo M, Ikeda K, Izumi N, Tateishi R, Ikeda M, et al. REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to Sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset. J Gastroenterol. 2020;55(1):113\u201322. https:\/\/doi.org\/10.1007\/s00535-019-01642-1.","journal-title":"J Gastroenterol"},{"key":"15621_CR34","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/2045-824X-6-18","volume":"6","author":"Y Yamamoto","year":"2014","unstructured":"Yamamoto Y, Matsui J, Matsushima T, Obaishi H, Miyazaki K, Nakamura K, et al. Lenvatinib, an angiogenesis inhibitor targeting VEGFR\/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. Vasc Cell. 2014;6:18. https:\/\/doi.org\/10.1186\/2045-824X-6-18.","journal-title":"Vasc Cell"},{"issue":"13","key":"15621_CR35","doi-asserted-by":"publisher","first-page":"17768","DOI":"10.18632\/aging.203268","volume":"13","author":"B Cao","year":"2021","unstructured":"Cao B, Guo X, Huang L, Wang B, Wang W, Han D, et al. Methylation Silencing CDH23 is a poor prognostic marker in diffuse large B-cell lymphoma. Aging. 2021;13(13):17768\u201388. https:\/\/doi.org\/10.18632\/aging.203268.","journal-title":"Aging"},{"issue":"2","key":"15621_CR36","doi-asserted-by":"publisher","first-page":"101422","DOI":"10.1016\/j.jcmgh.2024.101422","volume":"19","author":"J Tsuchiya","year":"2025","unstructured":"Tsuchiya J, Miyoshi M, Kakinuma S, Kawai-Kitahata F, Kamiya A, Shimizu T, et al. Hepatitis B Virus-KMT2B integration drives hepatic oncogenic processes in a human Gene-edited induced pluripotent stem Cells-derived model. Cell Mol Gastroenterol Hepatol. 2025;19(2):101422. https:\/\/doi.org\/10.1016\/j.jcmgh.2024.101422.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"1","key":"15621_CR37","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/s12885-024-12040-z","volume":"24","author":"J Wonglhow","year":"2024","unstructured":"Wonglhow J, Sunpaweravong P, Sathitruangsak C, Dechaphunkul A. LABS score- a prognostic tool for FOLFOX4-treated advanced hepatocellular carcinoma and real-world efficacy: a single-center retrospective study. BMC Cancer. 2024;24(1):281. https:\/\/doi.org\/10.1186\/s12885-024-12040-z.","journal-title":"BMC Cancer"},{"issue":"7","key":"15621_CR38","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1097\/CM9.0000000000002598","volume":"136","author":"X Hu","year":"2023","unstructured":"Hu X, Zheng Z, Han J, Li B, Guo G, Guo P, et al. Effect of intra-operative chemotherapy with 5-fluorouracil and leucovorin on the survival of patients with colorectal cancer after radical surgery: a retrospective cohort study. Chin Med J (Engl). 2023;136(7):830\u20139. https:\/\/doi.org\/10.1097\/CM9.0000000000002598.","journal-title":"Chin Med J (Engl)"},{"key":"15621_CR39","doi-asserted-by":"crossref","unstructured":"Zhang F, Hu K, Liu W, Quan B, Li M, Lu S, et al.\u00a0Oxaliplatin-Resistant Hepatocellular Carcinoma Drives Immune Evasion Through PD-L1 Up-Regulation and PMN-Singular Recruitment. Cell Mol Gastroenterol Hepatol. 2023;15(3):573\u201391.","DOI":"10.1016\/j.jcmgh.2022.12.002"},{"issue":"4","key":"15621_CR40","doi-asserted-by":"publisher","first-page":"4033","DOI":"10.3390\/ijms24044033","volume":"24","author":"S Shen","year":"2023","unstructured":"Shen S, Tu C, Shen H, Li J, Frangou C, Zhang J, et al. Comparative proteomics analysis of exosomes identifies key pathways and protein markers related to breast cancer metastasis. Int J Mol Sci. 2023;24(4):4033.\u00a0https:\/\/doi.org\/10.3390\/ijms24044033.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"15621_CR41","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/cac2.12278","volume":"42","author":"XD Zhu","year":"2022","unstructured":"Zhu XD, Huang MZ, Wang YS, Feng WJ, Chen ZY, He YF, et al. XELOX doublet regimen versus EOX triplet regimen as first-line treatment for advanced gastric cancer: an open-labeled, multicenter, randomized, prospective phase III trial (EXELOX). Cancer Commun (Lond). 2022;42(4):314\u201326. https:\/\/doi.org\/10.1002\/cac2.12278.","journal-title":"Cancer Commun (Lond)"},{"issue":"7","key":"15621_CR42","doi-asserted-by":"publisher","first-page":"e1753","DOI":"10.1002\/ctm2.1753","volume":"14","author":"B Yao","year":"2024","unstructured":"Yao B, Xing M, Zeng X, Zhang M, Zheng Q, Wang Z, et al. KMT2D-mediated H3K4me1 recruits YBX1 to facilitate triple-negative breast cancer progression through epigenetic activation of c-Myc. Clin Transl Med. 2024;14(7):e1753. https:\/\/doi.org\/10.1002\/ctm2.1753.","journal-title":"Clin Transl Med"},{"issue":"1","key":"15621_CR43","doi-asserted-by":"publisher","first-page":"6755","DOI":"10.1038\/s41467-024-50861-5","volume":"15","author":"W Liu","year":"2024","unstructured":"Liu W, Cao H, Wang J, Elmusrati A, Han B, Chen W, et al. Histone-methyltransferase KMT2D deficiency impairs the Fanconi anemia\/BRCA pathway upon glycolytic Inhibition in squamous cell carcinoma. Nat Commun. 2024;15(1):6755. https:\/\/doi.org\/10.1038\/s41467-024-50861-5.","journal-title":"Nat Commun"},{"issue":"1","key":"15621_CR44","doi-asserted-by":"publisher","first-page":"15","DOI":"10.7150\/ijbs.83586","volume":"20","author":"W Zhou","year":"2024","unstructured":"Zhou W, Lim A, Edderkaoui M, Osipov A, Wu H, Wang Q,et al. Role of YAP signaling in regulation of programmed cell death and drug resistance in cancer. Int J Biol Sci. 2024;20(1):15\u201328. https:\/\/doi.org\/10.7150\/ijbs.83586.","journal-title":"Int J Biol Sci"},{"issue":"1","key":"15621_CR45","doi-asserted-by":"publisher","first-page":"15735","DOI":"10.1038\/s41598-023-42560-w","volume":"13","author":"J Li","year":"2023","unstructured":"Li J, Lv M, Huang Q, Hu R, Zhong X, Sun X, et al. FAT4 expression in peripheral blood mononuclear cells is associated with prognosis and immune cell infiltration in hepatocellular carcinoma. Sci Rep. 2023;13(1):15735. https:\/\/doi.org\/10.1038\/s41598-023-42560-w.","journal-title":"Sci Rep"},{"issue":"18","key":"15621_CR46","doi-asserted-by":"publisher","first-page":"e108647","DOI":"10.15252\/embj.2021108647","volume":"40","author":"S Brabletz","year":"2021","unstructured":"Brabletz S, Schuhwerk H, Brabletz T, Stemmler MP. Dynamic EMT: a multi-tool for tumor progression. EMBO J. 2021;40(18):e108647.\u00a0https:\/\/doi.org\/10.15252\/embj.2021108647.","journal-title":"EMBO J"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15621-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15621-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15621-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T11:26:11Z","timestamp":1778153171000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15621-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,28]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15621"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15621-2","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,28]]},"assertion":[{"value":"21 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study protocol complied with the Declaration of Helsinki and was approved by the Ethics Committee of the First Affiliated Hospital of Chongqing Medical University (Approval No. 2019-021). The trial was registered at the Chinese Clinical Trial Registry (Registration No. ChiCTR1900022193).Written informed consent was obtained from all 51 participants prior to enrollment. The consent process included study participation, genetic data handling and publication consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This study report does not contain any identifiable patient data, so specific consent for publication is not required. The statement \u201cnot applicable\u201d is used in this section.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"582"}}